JAK Of All Trades: Janus Kinase Inhibitors Are Ready, Willing And Orally Available For Many Diseases
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Orally available, flexible and novel, Janus kinase inhibitors are poised to trigger major treatment shakeups in at least two disease spaces. Two drugs at the head of the JAK pack are close to coming of age – Pfizer Inc.’s tofacitinib and Incyte Corp.’s ‘18424 – and hopes are high, though questions remain about selectivity, long-term side effects and just how far the class can go.
You may also be interested in...
JAK Inhibitors Start To Come Of Age In Rheumatoid Arthritis
Oral class has gotten off to slow start, but data for range of JAK inhibitors – including Lilly’s once-daily baricitinib – presented at American College of Rheumatology meeting are encouraging.
With Remicade Biosimilar On The Rise, J&J Adds Astellas’ JAK2 To Pipeline
The unknowns of JAK inhibitors still offer substantial promise, and Pfizer will likely be the first test subject in the RA space.
With Remicade Biosimilar On The Rise, J&J Adds Astellas’ JAK2 To Pipeline
The unknowns of JAK inhibitors still offer substantial promise, and Pfizer will likely be the first test subject in the RA space.